“This document represents a collective effort to refine and advance the standards of care in STEMI management," according to one cardiologist behind the project. 

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Deaths related to obesity have skyrocketed in the United States, especially among men. However, researchers identified positive progress when it came to the mortality rates for CVD, ischemic heart disease and heart failure/cardiomyopathy.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Reliability modeling suggests the small-diameter defibrillation lead, already linked to positive early outcomes, should last patients for at least 10 years—and likely longer. 

Something as simple as resting a patient's arm the wrong way can make their BP reading inaccurate. 

While the initial purchase price was $600 million, the final amount could reach approximately $1.7 billion if certain milestones are met. V-Wave's Ventura Interatrial Shunt System for HFrEF has gained considerable interest in recent years, and Johnson & Johnson was an early investor in the technology back in 2016.

The FDA clearly sees significant potential in this new screening software from New York-based AccurKardia.